XOMA Acquires IXINITY Asset from Aptevo Therapeutics

XOMA has acquired the commercial payment and a portion of the milestone rights to IXINITY [coagulation factor IX (recombinant)], which is marketed by Medexus Pharmaceuticals for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Aptevo Therapeutics. XOMA has acquired rights related to IXINITY for $9.6 million.

“Adding a new commercial payment stream will benefit XOMA’s shareholders as we build our base of consistent incoming cash flows to help accelerate our royalty aggregation strategy,” said Brad Sitko, chief investment officer at XOMA. “IXINITY has an established niche in the Hemophilia B treatment paradigm, with near-term potential opportunities for growth, including label and geographic expansion.”

In the second quarter of 2023, XOMA will begin receiving a mid-single digit percentage payment stream on all IXINITY sales from January 1, 2023, into the first quarter of 2035 and also will be entitled to milestone payments.